154 related articles for article (PubMed ID: 35169860)
21. HEG1 indicates poor prognosis and promotes hepatocellular carcinoma invasion, metastasis, and EMT by activating Wnt/β-catenin signaling.
Zhao YR; Wang JL; Xu C; Li YM; Sun B; Yang LY
Clin Sci (Lond); 2019 Jul; 133(14):1645-1662. PubMed ID: 31278131
[TBL] [Abstract][Full Text] [Related]
22. SIP1 is downregulated in hepatocellular carcinoma by promoter hypermethylation.
Acun T; Oztas E; Yagci T; Yakicier MC
BMC Cancer; 2011 Jun; 11():223. PubMed ID: 21645397
[TBL] [Abstract][Full Text] [Related]
23. KRAB zinc-finger protein 382 regulates epithelial-mesenchymal transition and functions as a tumor suppressor, but is silenced by CpG methylation in gastric cancer.
Pei L; He X; Li S; Sun R; Xiang Q; Ren G; Xiang T
Int J Oncol; 2018 Sep; 53(3):961-972. PubMed ID: 29956735
[TBL] [Abstract][Full Text] [Related]
24. EZH2 promotes hepatocellular carcinoma progression through modulating miR-22/galectin-9 axis.
Chen S; Pu J; Bai J; Yin Y; Wu K; Wang J; Shuai X; Gao J; Tao K; Wang G; Li H
J Exp Clin Cancer Res; 2018 Jan; 37(1):3. PubMed ID: 29316949
[TBL] [Abstract][Full Text] [Related]
25. Epigenetic identification of ubiquitin carboxyl-terminal hydrolase L1 as a functional tumor suppressor and biomarker for hepatocellular carcinoma and other digestive tumors.
Yu J; Tao Q; Cheung KF; Jin H; Poon FF; Wang X; Li H; Cheng YY; Röcken C; Ebert MP; Chan AT; Sung JJ
Hepatology; 2008 Aug; 48(2):508-18. PubMed ID: 18666234
[TBL] [Abstract][Full Text] [Related]
26. Methylation of S100A8 is a promising diagnosis and prognostic marker in hepatocellular carcinoma.
Liu K; Zhang Y; Zhang C; Zhang Q; Li J; Xiao F; Li Y; Zhang R; Dou D; Liang J; Qin J; Lin Z; Zhao D; Jiang M; Liang Z; Su J; Gupta VP; He M; Yang X
Oncotarget; 2016 Aug; 7(35):56798-56810. PubMed ID: 27462864
[TBL] [Abstract][Full Text] [Related]
27. Identification by TCGA database search of five genes that are aberrantly expressed and involved in hepatocellular carcinoma potentially via DNA methylation changes.
Matsushita J; Suzuki T; Okamura K; Ichihara G; Nohara K
Environ Health Prev Med; 2020 Jul; 25(1):31. PubMed ID: 32703154
[TBL] [Abstract][Full Text] [Related]
28. Clinical and biological significance of miR-23b and miR-193a in human hepatocellular carcinoma.
Grossi I; Arici B; Portolani N; De Petro G; Salvi A
Oncotarget; 2017 Jan; 8(4):6955-6969. PubMed ID: 28036298
[TBL] [Abstract][Full Text] [Related]
29. Aberrant CpG island hypermethylation and down-regulation of Oct-6 mRNA expression in human hepatocellular carcinoma.
Sun JZ; Yang XX; Li XH; Xu WW; Wang Y; Zhu W; Li M
Dig Dis Sci; 2011 Oct; 56(10):3072-7. PubMed ID: 21448695
[TBL] [Abstract][Full Text] [Related]
30. Epigenetic silencing of TMEM176A activates ERK signaling in human hepatocellular carcinoma.
Li H; Zhang M; Linghu E; Zhou F; Herman JG; Hu L; Guo M
Clin Epigenetics; 2018 Nov; 10(1):137. PubMed ID: 30400968
[TBL] [Abstract][Full Text] [Related]
31. Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3 sigma gene in human hepatocellular carcinoma.
Iwata N; Yamamoto H; Sasaki S; Itoh F; Suzuki H; Kikuchi T; Kaneto H; Iku S; Ozeki I; Karino Y; Satoh T; Toyota J; Satoh M; Endo T; Imai K
Oncogene; 2000 Nov; 19(46):5298-302. PubMed ID: 11077447
[TBL] [Abstract][Full Text] [Related]
32. Identification of LZAP as a new candidate tumor suppressor in hepatocellular carcinoma.
Zhao JJ; Pan K; Li JJ; Chen YB; Chen JG; Lv L; Wang DD; Pan QZ; Chen MS; Xia JC
PLoS One; 2011; 6(10):e26608. PubMed ID: 22028922
[TBL] [Abstract][Full Text] [Related]
33. RASSF10 is an epigenetically inactivated tumor suppressor and independent prognostic factor in hepatocellular carcinoma.
Wang F; Feng Y; Li P; Wang K; Feng L; Liu YF; Huang H; Guo YB; Mao QS; Xue WJ
Oncotarget; 2016 Jan; 7(4):4279-97. PubMed ID: 26701853
[TBL] [Abstract][Full Text] [Related]
34. Deregulation of RB1 expression by loss of imprinting in human hepatocellular carcinoma.
Anwar SL; Krech T; Hasemeier B; Schipper E; Schweitzer N; Vogel A; Kreipe H; Lehmann U
J Pathol; 2014 Aug; 233(4):392-401. PubMed ID: 24838394
[TBL] [Abstract][Full Text] [Related]
35. Expression and inhibitory role of TIMP-3 in hepatocellular carcinoma.
Shen B; Jiang Y; Chen YR; Zheng HC; Zeng W; Li YY; Yin A; Nie Y
Oncol Rep; 2016 Jul; 36(1):494-502. PubMed ID: 27222429
[TBL] [Abstract][Full Text] [Related]
36. Hypermethylation of FOXD3 suppresses cell proliferation, invasion and metastasis in hepatocellular carcinoma.
He G; Hu S; Zhang D; Wu P; Zhu X; Xin S; Lu G; Ding Y; Liang L
Exp Mol Pathol; 2015 Oct; 99(2):374-82. PubMed ID: 26112097
[TBL] [Abstract][Full Text] [Related]
37. LncRNA SBF2-AS1 promotes hepatocellular carcinoma metastasis by regulating EMT and predicts unfavorable prognosis.
Zhang YT; Li BP; Zhang B; Ma P; Wu QL; Ming L; Xie LM
Eur Rev Med Pharmacol Sci; 2018 Oct; 22(19):6333-6341. PubMed ID: 30338801
[TBL] [Abstract][Full Text] [Related]
38. JARID2 promotes invasion and metastasis of hepatocellular carcinoma by facilitating epithelial-mesenchymal transition through PTEN/AKT signaling.
Lei X; Xu JF; Chang RM; Fang F; Zuo CH; Yang LY
Oncotarget; 2016 Jun; 7(26):40266-40284. PubMed ID: 27259236
[TBL] [Abstract][Full Text] [Related]
39. Pharmacological unmasking microarray approach-based discovery of novel DNA methylation markers for hepatocellular carcinoma.
Jung N; Won JK; Kim BH; Suh KS; Jang JJ; Kang GH
J Korean Med Sci; 2012 Jun; 27(6):594-604. PubMed ID: 22690089
[TBL] [Abstract][Full Text] [Related]
40. Screening and verification of microRNA promoter methylation sites in hepatocellular carcinoma.
Ni X; Lin Z; Dai S; Chen H; Chen J; Zheng C; Wu B; Ao J; Shi K; Sun H
J Cell Biochem; 2020 Jul; 121(7):3626-3641. PubMed ID: 32065423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
